AkaRx was a biopharmaceutical company formed as a spin-out of the merger of Yamanouchi Pharmaceutical and Fujisawa Health care. AkaRx developed therapeutic treatments that addresses unmet medical needs and provided significant benefits over currently available therapies. The company's lead product, AKR-501, t platelet disorders of diverse etiologies. Eisai Pharamaceuticals acquired AkaRx in 2009.